

The purpose of this questionnaire is to obtain information from the sponsor in order to facilitate and accelerate the process of study submission. Please complete this questionnaire prior to the pre-site selection visit (PSV) or call. If a PSV is not required, please complete the form and submit with the full regulatory start-up package.

Study Number:						
Study Title:						
STUDY TARGETS						
Study Length (in months)		ual Length n months)	Total Sites	Total Accrua	al U-M Accrual	
Comments:						
STUDY PROGRESS						
Active Current Sites (#) Accrual		Activation Date Initial Visit Date of Initial Site of First Patient			Final Visit Date of Last Patient	
		Projected Actual	Projected	Actual	Projected	
Projected Number of Data Locks & Interim Analysis?						
Projected Databas	se Closure &	Site Termination? (ex.: sa	ix months after last patient o	ff-study)		
Is there an amendment in progress?					Yes No	
If yes, please provided the projected date of release?						
If yes, can sites enroll under the current protocol if approved prior to receipt of the new amendment?					Yes No	
Comments:						



#### **STUDY DOCUMENT**

In addition to the regulatory start-up documents (i.e., protocol, informed consent, investigator brochure, etc.), the following documents are required for submission. If they are not received in a timely manner, protocol activation may be delayed. Please indicate the status of availability for the following documents, if applicable.

Proposed study budget and contract	N/A	Yes	No, available by:
Laboratory Manual	N/A	Yes	No, available by:
Pharmacy Manual	N/A	Yes	No, available by:
EKG Manual	N/A	Yes	No, available by:
IVRS/IWRS Manual	N/A	Yes	No, available by:
Study Reference Manuals	N/A	Yes	No, available by:
Case Report Forms (CRFs)	N/A	Yes	No, available by:
CRF Completion Guidelines	N/A	Yes	No, available by:
Eligibility Checklist / Enrollment Form	N/A	Yes	No, available by:
Serious Adverse Event (SAE) Form	N/A	Yes	No, available by:
Contact List for CRO(s) and Vendor(s)	N/A	Yes	No, available by:
Contact List for Sponsor(s)	N/A	Yes	No, available by:
Subject Completed Questionnaires*	N/A	Yes	No, available by:
Subject Completed Oral Drug Diaries*	N/A	Yes	No, available by:

<sup>\*</sup> requires approval by IRB



### ADDITIONAL ITEMS FOR PLANNING

The following items will assist us in resource planning, budgeting, and coordinating across other internal units to ensure expedient approval and successful completion of the study.

Will any equipment be provided? (ex: ECG machine, infusion pump, e-Diaries, etc.)	Yes No
If yes, list:	
L Note: Please provide this equipment as soon as available.  Inspection & approval by our Biomedical Engineering Un	it (BEU) is required prior to IRB Approval.
Do any of the following require central review & results confirmation prior to enrollment?	Tissue Imaging
Is the site required to use central lab results to determine eligibility or subsequent dosing?	No Unknown
Is the study utilizing an IVRS/IWRS system?	No Unknown
If yes, indicate below all that apply:  Drug Inventory Drug Assignments Patient Statuses	Visit Confirmation Only
If used for patient statuses, indicate below all that apply:  Screening Registration Randomization	Other
If applicable, FDG PET Scan and/or MUGA required (as an additional committee approval will be needed)?	No Unknown
Will any scans (MRI, CT, PET, etc.) be considered "research" only, not standard of care (requires different internal radiology coordination)?	No Unknown
Will the study be using a central imaging vendor reviewer?  Yes	No Unknown
If yes, does the site need to pre-qualify with the imaging vendor?	No Unknown
If yes, what is involved in the pre-qualification process? (Examples: phantom, standard-of-care deidentification transmission to vendor, etc.)	
If yes, can site-initiation visit be held prior to qualification of site?	No Unknown
Will PK/PD/Genetic sample collection be required?  Yes	No Unknown



Will special sample processing / additives / timeframe	Yes	No	Unknown	
If yes, explain:				
Will the study utilize an electronic data capture system	n (EDC)?	Yes	No	Unknown
If yes, what is the EDC vendor?				
Are serious adverse events reported via the EDC?		Yes	No	Unknown
If yes, will some data entry be required only by the	Yes	No	Unknown	
If yes, indicate which SAE elements?	Entire Repor	t Gr	ade	Attribution
Will you need to monitor within two weeks of the first on study?	t patient going	Yes	No	Unknown
Will the study at any point move into analytical risk-bamonitoring?	ased	Yes	No	Unknown
How frequently do you anticipate intermediate "on-site" monitoring visits will be scheduled?				
How frequently do you anticipate intermediate "remote" monitoring visits will be scheduled?				
Will you use remote monitoring?		Yes	No	Unknown
Will the sponsor have regularly scheduled teleconfere	nces?	Yes	No	Unknown
Is this study considered approved by the FDA? (i.e., date of receipt of the IND by FDA is greater than 30 days or sponsor h notification by the FDA that studies may begin.)	as received earlier	Yes	No	Unknown

Thank you for considering the University of Michigan for this important study.

www.clinicaltrials.med.umich.edu

Questions? Email CTSOgroup@umich.edu